For patients with Alagille syndrome


LIVMARLI is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome who are 1 year old1


Improves cholestatic pruritus vs baseline1

Downard Chart Line

Reduces serum bile acid (sBA) levels vs baseline1


Well-characterized safety and tolerability profile backed by >5 years of safety data1,2*

*The majority of exposure occurred without a placebo control in open-label extensions.

References: 1. LIVMARLI™ (maralixibat) oral solution. Prescribing Information. Mirum Pharmaceuticals, Inc. 2. Raman RK, Garner W, Vig P, Tucker E. An integrated analysis of long-term clinical safety in maralixibat-treated participants with Alagille syndrome. Poster presented at: European Association for the Study of the Liver (EASL) International Liver Congress; June 23-26, 2021.

Two Ways to Prescribe LIVMARLI

Download the Patient Enrollment Form, fill it out, and fax it to Mirum Access Plus (MAP) at (855) 282-4884.

Submit an eRX through your electronic medical records straight to Eversana, our single-source specialty pharmacy.


Exclamation Point

From Prescription to Refill, Access Support Is Available for Every Step With the Mirum Access Plus (MAP) Support Program

Ways to Prescribe LIVMARLI

If you’d like to prescribe LIVMARLI for your patient, download the Patient Enrollment Form. Once you have filled out the form, fax it to MAP to prescribe LIVMARLI and/or have your patient consent for MAP services.

Download the Patient Enrollment Form

You can also digitally prescribe LIVMARLI through your electronic medical records by submitting an eRX straight to Eversana Life Science Services, our single-source specialty pharmacy.

Refer to this step-by-step guide for more information on prescribing LIVMARLI.

MAP is available to help you, your office, and your patients not only get started with LIVMARLI after you’ve prescribed it, but also to provide support throughout treatment.

Read on to learn about the details of MAP support or see the resources available to you and your patients.

If you have any questions about MAP, contact us at 1‑855‑MRM‑4YOU (1‑855‑676‑4968) Monday through Friday, 8:00 AM through 8:00 PM ET.

Mirum Access Plus (MAP) Logo
Ready, Set, Go:

Getting Your Patients the Treatment They Need

Support and resources are available through MAP to help you and your office navigate insurance coverage, as well as assist your patients in treatment costs and prescription fulfillment.

Icon - Insurance Coverage

Insurance Coverage and Access Support

Throughout the payer approval process, MAP works closely with you, your patients, and the insurance plan to help ensure patients get the treatment they need. Consider the following resources to help your patients access LIVMARLI:

Money Icon - Financial Support

Financial Support for Patients

MAP provides financial support options:

  • MAP Savings Program*: Eligible patients with commercial or private insurance will pay as little as a $10 out-of-pocket cost for LIVMARLI, subject to the program’s terms, conditions, and limits. This program is provided to patients by the manufacturer of the medication
  • Patient Assistance Program: Provides LIVMARLI at no cost for up to one calendar year for eligible patients without insurance coverage, subject to the program’s terms, conditions, and limits
Eligible patients may pay
as little as a $10 out of
pocket cost for LIVMARLI.*
Star Icon - Single Source Specialty Pharmacy

Single-Source Specialty Pharmacy

MAP is a single-source specialty pharmacy that will ship LIVMARLI directly to patients, provide 24/7 access to pharmacists, and proactively manage refills.

*Eligibility Restrictions: This program is not available to individuals who use any state or federal government-funded healthcare program to cover a portion of medication costs, such as Medicare, Medicaid, TRICARE, Department of Defense, Veterans Administration, or any other state or federal government-funded healthcare program.

By Your Side at Every Turn

A Team Dedicated to Alagille Syndrome

Focus on what matters and leave the rest to our experienced and dedicated team at MAP, who will work with your office staff through the access process and assist your patients at every turn.

Icon - MAP Coordinators

MAP Coordinators

Available to your office staff and your patients, MAP Coordinators are experts who specialize in the insurance coverage process and available financial support options.

Icon - Experienced Navigators

Experienced Navigators

Navigators will connect with your patients to provide health education and the emotional support needed to address the difficulties of living with Alagille syndrome.

Mirum Access PLUS

Even More to Help Patients Start and Stay on Therapy

In addition to helping your patients get the treatment they need, MAP offers educational resources and tools for patients who sign up for the program, as described in the MAP Brochure.

Your Patients Can Easily Enroll in MAP

Speak with your patients about enrolling in the MAP support program through one of the following options.

Text “ENROLL” to 1-833-MAP-4YOU (1-833-627-4968)
Download the Patient 
Consent Form
and fax to MAP at (855) 282-4884

Consider providing the MAP Brochure to help familiarize your patients with all that MAP has to offer them.

If your patients choose to enroll in the enhanced MAP program, they will have access to an even wider range of support services tailored to them—at no cost:

  • Personalized support: Navigators can provide support for both medication and overall wellness. They can make personal recommendations on helpful educational resources and tools to support ongoing disease and treatment management
  • Drive adherence: Navigators can help reinforce adherence by introducing and discussing symptom-tracking tools and encouraging communication between patients and their physicians about cholestatic pruritus levels
  • Convenient interactions: MAP Mobile allows your patients to interact with the program through their mobile devices. Patients can easily provide insurance information and e-sign documents to speed up processing
Boy protecting the fort

Support Is a Click Away

Resources for You and Your Patients

Several resources are available to help you prescribe and access LIVMARLI for your patients. Patient-friendly resources are also available to share and discuss with your patients.

Mirum Access Plus (MAP) Resources for Health Care Professionals

Download and fax this form to MAP to prescribe LIVMARLI and/or have your patient enroll in MAP support.

Refer to this step-by-step guide for more information on prescribing LIVMARLI.

Download and use this template letter of medical necessity to support the payer approval process with insurance plans.

Keep these tips and questions in mind to help with coverage determination for your patients.

These are some steps that may help if your patients’ insurance plans’ prior authorization or medical exception is denied.

Consider this digital option to enroll your patients in MAP support, easily provide their insurance information, and e-sign documents to speed up processing.

LIVMARLI Resources for Patients

Share this website with your patients to explain LIVMARLI treatment in a patient-friendly manner.

Mirum Access Plus (MAP) Resources for Patients

This resource helps explain to your patients the initial process of receiving a LIVMARLI prescription and treatment.

This brochure summarizes the MAP support available to your patients.

Patients can enroll in the support program by texting ENROLL to 1-833-MAP-4YOU (1-833-627-4968). Or, they can download and sign the Patient Consent Form to sign up.

Go to the Patient Website to have patients sign up for MAP support through their mobile phones.

Check it. Chart it. Discuss it.

Itch✓ is a simple yet detailed symptom journal designed to help both you and your patients and their caregivers make sense of itch severity and more.


  1. Learn patterns to make sense of symptoms: Your patients and their caregivers will see symptom patterns over time with charts based on their observations.
  2. Stay organized with all entries in one place: Your patients’ and their caregivers’ observations will be categorized based on date and entry type, making it easy for them to view and edit entries.
  3. Share reports to keep YOU in the know: A weekly report generated by Itch✓ will help your patients and their caregivers be better prepared for their upcoming visits with you. Reports include average itch severity, growth percentile data, photos, notes, and more.

Apple® and App Store® are registered trademarks of Apple Inc.

Expand ISI Button Collapse ISI Button


LIVMARLI is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older.

Important Safety Information

Warnings and Precautions

Liver Test Abnormalities: Patients enrolled in clinical trials had abnormal liver tests at baseline. In the main clinical trial, treatment-emergent elevations or worsening of liver tests (ALT, AST, or T/DB) relative to baseline were observed. Obtain baseline liver tests and monitor during treatment. Dose reduction or treatment interruption may be considered if abnormalities occur in the absence of other causes. For persistent or recurrent liver test abnormalities, consider treatment discontinuation. Discontinue permanently if a patient progresses to portal hypertension or experiences a hepatic decompensation event.

GI Adverse Reactions: Diarrhea, abdominal pain, and vomiting were reported as the most common adverse reactions. If diarrhea, abdominal pain, and/or vomiting occur and no other etiologies are found, consider reducing the dose or interrupting LIVMARLI. For diarrhea or vomiting, monitor for dehydration and treat promptly. Consider interrupting LIVMARLI dosing if a patient experiences persistent diarrhea or has diarrhea with accompanying signs and symptoms such as bloody stool, vomiting, dehydration requiring treatment, or fever. Restart LIVMARLI at 190 mcg/kg/day when diarrhea, abdominal pain, or vomiting resolve, and increase the dose as tolerated. If they recur upon re-challenge, consider stopping LIVMARLI treatment.

Fat-Soluble Vitamin Deficiency: ALGS patients can have fat-soluble vitamin (FSV) deficiency (vitamins A, D, E, and K) at baseline, and LIVMARLI may affect absorption of FSV. In the main clinical trial, treatment emergent FSV deficiency was reported in 3 (10%) patients during 48 weeks of treatment. Obtain baseline serum levels and monitor during treatment, along with any clinical manifestations. Supplement if deficiency is observed. Consider discontinuing LIVMARLI if FSV deficiency persists or worsens despite adequate FSV supplementation.

Adverse Reactions

The most common adverse reactions (≥5%) are diarrhea, abdominal pain, vomiting, fat-soluble vitamin deficiency, liver test abnormalities, gastrointestinal bleeding, and bone fractures.

Drug Interactions

Administer bile acid binding resins at least 4 hours before or 4 hours after administration of LIVMARLI.

A decrease in the absorption of OATP2B1 substrates (eg, statins) due to OATP2B1 inhibition by LIVMARLI in the GI tract cannot be ruled out. Consider monitoring the drug effects of OATP2B1 substrates as needed.

Please see full Prescribing Information for LIVMARLI.